4.35 0.00 (0.00%)
After hours: 4:21PM EDT
|Bid||4.25 x 27000|
|Ask||4.40 x 1100|
|Day's Range||4.30 - 4.65|
|52 Week Range||2.80 - 13.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2018 - May 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Immune Design (IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced preclinical and translational data that support the mechanism of action of G100 in patients with indolent non-Hodgkin Follicular lymphomas (FL). The research presented was designed to understand why high TLR 4 expression in patient’s samples correlated with clinical responses to G100 treatment.
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2018-- Immune Design, an immunotherapy company focused on novel therapies in oncology, today announced that the company will host an event featuring key ...
Immune Design (IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced the launch of the patient and healthcare provider websites for the SYNOVATE study – a pivotal trial to evaluate CMB305 immunotherapy in synovial sarcoma patients. “Patients with advanced synovial sarcoma often have few systemic treatment options immediately after they complete first line chemotherapy.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Immune Design Corp. (NASDAQ: IMDZ), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.
The Seattle-based company said it had a loss of 28 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3 The 20 ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10 ug dose Conference call at 1:30 pm ...
During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 25, 2018-- Immune Design, an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 ...
Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The most recent earnings update Immune Design Corp’s (NASDAQ:IMDZ) released in December 2017 signalled that losses became smaller relative to the prrior year’s level – great news for investors Below,Read More...
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
The Seattle-based company said it had a loss of 29 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
Assessing Immune Design Corp’s (NASDAQ:IMDZ) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...
We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.
Immune Design and Westlake Chemical Partners are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in theRead More...